8-K: Option Care Health Announces Strong Preliminary 2024 Results and $500 Million Share Repurchase Program

Option Care Health reported preliminary unaudited financial results for 2024, exceeding $4.99 billion in revenue, and announced a new $500 million stock repurchase program.

Summary

• Option Care Health announced preliminary unaudited financial results for the fourth quarter and full year 2024.
• The company expects net revenue between $1.34 billion and $1.35 billion for Q4 2024, representing a 19.2% to 20.1% growth over the same period in 2023.
• Net income for Q4 2024 is projected to be between $56.8 million and $60.9 million, with diluted earnings per share between $0.33 and $0.36.
• Adjusted EBITDA for Q4 2024 is expected to be between $118.7 million and $121.7 million, a 6.4% to 9.1% increase year-over-year.
• For the full year 2024, net revenue is expected to be between $4.99 billion and $5.00 billion, a 16.0% to 16.2% increase over the prior year.
• Full year 2024 net income is projected to be between $208.5 million and $212.6 million, with diluted earnings per share between $1.21 and $1.23.
• Adjusted EBITDA for the full year 2024 is expected to be between $441.0 million and $444.0 million, a 3.7% to 4.4% increase over the prior year.
• The company anticipates cash flow from operations of at least $300 million for 2024 and cash and cash equivalents of approximately $412.6 million.
• Preliminary full year 2025 guidance includes net revenue between $5.2 billion and $5.4 billion, adjusted EBITDA between $445 million and $465 million, and adjusted EPS between $1.59 and $1.69.
• This 2025 guidance incorporates a negative gross profit impact of $60 million to $70 million due to Stelara pricing adjustments.
• A new $500 million stock repurchase program was approved by the Board of Directors on January 10, 2025, with no specified expiration date.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, a new share repurchase program, and positive future guidance. However, the negative impact of Stelara pricing adjustments and the preliminary nature of the results temper the overall optimism.

Positives

• The company is experiencing strong revenue growth, with a projected 16% increase for the full year 2024.
• Adjusted EBITDA is also showing positive growth, both for the fourth quarter and the full year 2024.
• Option Care Health is generating strong cash flow from operations, with at least $300 million expected for 2024.
• The new $500 million stock repurchase program indicates confidence in the company's financial position and future prospects.
• The company has a diversified payer portfolio with the largest payer representing only ~15% of revenue.
• The company has a broad portfolio of chronic and acute therapies including more than 50 limited distribution therapies.
• The company has a robust national platform with comprehensive clinical solutions.
• The company has a consistent track record of cash flow generation and strategic capital deployment.
• The company has a balanced revenue and gross profit with more than 75% of product margin generated by generic and biosimilar therapies.

Negatives

• The company's 2025 guidance includes a negative impact of $60 million to $70 million due to Stelara pricing adjustments.
• The preliminary financial results are subject to change upon completion of year-end closing procedures and further financial review.
• The company's independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to these estimated financial results.

Risks

• Changes in laws and regulations applicable to the business model could impact results.
• Changes in market conditions and receptivity to services and offerings could affect performance.
• Pending and future litigation could pose a risk to the company.
• Potential liability for claims not covered by insurance could impact financial results.
• Loss of relationships with managed care organizations and other non-governmental third-party payers could affect revenue.
• The preliminary financial results are subject to change and may differ from actual results.
• The Stelara pricing adjustments will negatively impact gross profit by $60 million to $70 million in 2025.

Future Outlook

Option Care Health expects continued growth in 2025, with revenue projected to reach between $5.2 billion and $5.4 billion, despite a negative impact from Stelara pricing adjustments. The company also plans to expand its infusion clinic footprint and explore emerging therapies.

Management Comments

• Management believes that adjusted measures provide useful supplemental information regarding the performance of Option Care Health's business operations and facilitate comparisons to the company's historical operating results.
• Management has not reconciled Adjusted EBITDA guidance to net income, nor Adjusted EPS guidance to GAAP earnings per share, as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items.

Industry Context

Option Care Health operates in the home and alternate site infusion services market, which is experiencing growth due to the increasing preference for home-based care and the rising prevalence of chronic diseases. The company's focus on a national platform and diverse therapy portfolio positions it well to capitalize on these trends. The company is a leading independent provider in a fragmented market.

Comparison to Industry Standards

• Option Care Health's revenue growth of 16% for 2024 is strong compared to the overall healthcare industry growth rate, which is typically in the single digits.
• The company's adjusted EBITDA growth of 4% is solid, but could be considered moderate compared to some high-growth healthcare technology companies.
• The company's focus on home infusion is in line with the industry trend of shifting care to lower-cost settings.
• The company's diversified payer mix reduces risk compared to companies heavily reliant on government payers.
• The company's expansion into limited distribution therapies is a positive sign, as these therapies often have higher margins.
• The company's share repurchase program is a common practice among mature companies with strong cash flow, similar to companies like CVS Health and Walgreens Boots Alliance.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and potential for increased stock value.
• Employees may experience job security and potential growth opportunities due to the company's expansion.
• Customers will benefit from the company's continued investment in clinical and operational capabilities.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may view the company as a lower risk due to its strong financial performance.

Next Steps

• The company will release full fourth quarter and full year results on February 26, 2025.
• The company will host a conference call to review the results on February 26, 2025.
• The company will continue to execute its share repurchase program.
• The company will continue to invest in clinical and operational capabilities.
• The company will continue to expand its portfolio of therapies.
• The company will continue to expand its Infusion Clinic footprint.
• The company will continue to invest in collaboration opportunities with pharma.

Key Dates

Keywords

infusion services, home healthcare, financial results, stock repurchase, adjusted EBITDA, revenue, earnings per share, healthcare, pharmacy, M&A